Vendor
5 published CVES affecting DEXMA, from public sources (CVE.org, NVD, CISA KEV, FIRST EPSS, OSV).
Newest publication first
The affected product is vulnerable to an exposure of sensitive information to an unauthorized actor vulnerability, which may allow an attacker to create malicious requests for obtaining the information of the version about the web server used.
The affected product is vulnerable to a cross-site request forgery vulnerability, which may allow an attacker to perform actions with the permissions of a victim user.
The affected product is vulnerable to an improper authentication vulnerability, which may allow an attacker to impersonate a legitimate user as long as the device keeps the session active, since the attack takes advantage of the cookie header to generate "legitimate" requests.
The affected product is vulnerable to a cleartext transmission of sensitive information vulnerability, which may allow an attacker with access to the network, where clients have access to the DexGate server, could capture traffic. The attacker can later us the information within...
The affected product is vulnerable to a cross-site scripting vulnerability, which could allow an attacker to access the web application to introduce arbitrary Java Script by injecting an XSS payload into the 'hostname' parameter of the vulnerable software.
Sources: CVE.org, NVD, CISA KEV, FIRST EPSS, OSV and public exploit-reference metadata. Product matching comes from the published CVE records. A proof-of-concept means public code exists; it is not evidence of exploitation.